Pain is inevitable for tumor patients, and analgesia is especially important to improve the quality of life of tumor patients. Pain treatment experts point out that there are often many misconceptions from doctors, family members, society to patients themselves due to poor understanding of the significance of analgesia. Myth 1: Analgesics can be addictive Some patients and their families are worried about morphine addiction and strongly disagree with the use of painkillers such as morphine. In fact, clinical research proves that it is very rare to have addiction to opioid drugs in regular doses for the purpose of analgesic treatment. The increase of medication for cancer pain patients is mostly a manifestation of the development of disease and physical tolerance of drugs, and physical dependence is a normal physiological pharmacological phenomenon, which cannot be a reason to stop medication. Some doctors and cancer patients think that pain will gradually increase as cancer progresses, and if strong painkillers are used at the beginning of pain, I am afraid there will be no other painkillers available at the late stage of the disease. In fact, the timely application of pain medication is safer, more effective, and requires the lowest strength and dose of painkillers. Cancer patients who are not treated with effective pain medication for a long time are more likely to develop neuropathic pain-related neurological dysfunction due to pain, which is clinically manifested as intractable pain such as nociceptive hypersensitivity and abnormal pain. Myth 3: Dulcolax is the first choice of painkillers Dulcolax plays a pivotal role in acute acute pain such as visceral pain, burns and postoperative pain relief. Patients and their families often regard Dulcolax as a panacea for cancer treatment, which is actually a misconception. In fact, Dulcolax injection among narcotic drugs should not be used as the drug of choice for cancer pain relief. The analgesic effect of dulcolax is only 1/8-1/10 of morphine, and its metabolite, desmethyl pethidine, has a long plasma half-life, and has potential neurotoxicity and nephrotoxicity. The World Health Organization has clearly stated that dulcolax is not suitable for the treatment of moderate to severe chronic pain. For pain relief in advanced cancer, morphine preparation is advocated, which is not only effective in pain relief but also rarely produces dependence, which is more conducive to pain control and improving the quality of life of advanced tumor patients.